RU94016196A - Method for treating the cases of abdominal typhoid - Google Patents

Method for treating the cases of abdominal typhoid

Info

Publication number
RU94016196A
RU94016196A RU94016196/14A RU94016196A RU94016196A RU 94016196 A RU94016196 A RU 94016196A RU 94016196/14 A RU94016196/14 A RU 94016196/14A RU 94016196 A RU94016196 A RU 94016196A RU 94016196 A RU94016196 A RU 94016196A
Authority
RU
Russia
Prior art keywords
solution
typhoid
disease
treating
unithiol
Prior art date
Application number
RU94016196/14A
Other languages
Russian (ru)
Other versions
RU2044543C1 (en
Inventor
Н.Д. Ющук
Д.Р. Ахмедов
В.М. Фролов
Н.А. Пересадин
Н.И. Хомутянская
В.В. Соколовский
Е.В. Костюшов
А.А. Тяптин
Original Assignee
Н.Д. Ющук
Д.Р. Ахмедов
В.М. Фролов
Н.А. Пересадин
Н.И. Хомутянская
В.В. Соколовский
Е.В. Костюшов
А.А. Тяптин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Н.Д. Ющук, Д.Р. Ахмедов, В.М. Фролов, Н.А. Пересадин, Н.И. Хомутянская, В.В. Соколовский, Е.В. Костюшов, А.А. Тяптин filed Critical Н.Д. Ющук
Priority to RU9494016196A priority Critical patent/RU2044543C1/en
Application granted granted Critical
Publication of RU2044543C1 publication Critical patent/RU2044543C1/en
Publication of RU94016196A publication Critical patent/RU94016196A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FIELD: medicine. SUBSTANCE: method involves administering antioxidant preparations like unithiol in addition to levomycetin therapy at a dose of 0.1 ml of 5% solution per 1 kg of body mass in combination with ascorbic acid in the amount of 1 ml of 5% solution per 2.5-3.5 ml of unithiol and alpha-tocopherol acetate at a dose of 1 ml of 10% solution administered intravenously twice a day during 5-10 days depending on the disease course severity degree. EFFECT: enhanced effectiveness of treatment.

Claims (1)

Проведенные исследования у больных брюшным тифом выявили нарушения функционального состояния отдельных компонентов неферментативного и ферментативного звеньев антиоксидантной системы (АОС). Предложен способ лечения больных брюшным тифом, позволяющий восстановить нарушения функционального состояния АОС и иммунного статуса, уменьшить частоту развития осложнений и рецидивов заболевания. Для этого наряду с левомицитином рекомендуется введение антиоксидантных препаратов: унитиол из расчета 0,1 мл 5%-ного раствора на 1 кг массы больного в сочетании с аскорбиновой кислотой из расчета 1 мл 5%-ного раствора на 2,5 - 3,5 мл унитиола и альфа-токоферола ацетата по 1 мл 10%-ного раствора внутримышечно 2 раза в сутки в течение 5 - 10 дней в зависимости от тяжести течения заболевания.Studies in patients with typhoid fever revealed impaired functional status of individual components of the non-enzymatic and enzymatic parts of the antioxidant system (AOS). A method is proposed for treating patients with typhoid fever, which allows to restore violations of the functional state of AOS and immune status, to reduce the incidence of complications and relapses of the disease. For this, along with levomycetin, the introduction of antioxidant drugs is recommended: unitiol at the rate of 0.1 ml of a 5% solution per 1 kg of the patient's weight in combination with ascorbic acid at the rate of 1 ml of a 5% solution at 2.5 - 3.5 ml unitiol and alpha-tocopherol acetate 1 ml of a 10% solution intramuscularly 2 times a day for 5 to 10 days, depending on the severity of the disease.
RU9494016196A 1994-05-17 1994-05-17 Method for treating patients suffering from typhoid fever RU2044543C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU9494016196A RU2044543C1 (en) 1994-05-17 1994-05-17 Method for treating patients suffering from typhoid fever

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU9494016196A RU2044543C1 (en) 1994-05-17 1994-05-17 Method for treating patients suffering from typhoid fever

Publications (2)

Publication Number Publication Date
RU2044543C1 RU2044543C1 (en) 1995-09-27
RU94016196A true RU94016196A (en) 1996-08-10

Family

ID=20155477

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9494016196A RU2044543C1 (en) 1994-05-17 1994-05-17 Method for treating patients suffering from typhoid fever

Country Status (1)

Country Link
RU (1) RU2044543C1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302768C (en) 1999-12-29 2007-03-07 谢尔盖米哈依洛维奇泽诺维奇 Physiologically active agents containing vicinal dithioglycols and use therof in various branches of economy
RU2157647C1 (en) * 1999-12-29 2000-10-20 Зенович Сергей Михайлович Food additive and method of preparation thereof, biologically-active food additive and method of preparation thereof, foodstuff and method of preparation thereof

Also Published As

Publication number Publication date
RU2044543C1 (en) 1995-09-27

Similar Documents

Publication Publication Date Title
AU7643591A (en) A pharmaceutical preparation
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
NO943901L (en) Methods and Preparations for the Treatment of Diseases with Interferon While Reducing Side Effects
DK0630230T3 (en) Pharmaceutical inhalation preparations
RU95101385A (en) Products containing g-csf and tnf-binding protein
JPH08512311A (en) Arsenic medicine for treating chronic fatigue syndrome
RU94016196A (en) Method for treating the cases of abdominal typhoid
Yoshikawa et al. Extremely acute phenytoin‐induced peripheral neuropathy
JPS58103324A (en) Interferon composition and use for herpes infection treatment
Ferrer et al. Prevention of therapeutically induced regression of sarcoma 180 by immunologic enhancement
ATE91890T1 (en) MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM.
JPH03500656A (en) Acyl carnitine, a drug for the treatment and prevention of viral infections
RU2108799C1 (en) Method of treatment of nodular erythema
SU1706624A1 (en) Method for curing opiumism and morphinism
SU1232257A1 (en) Method of treatment of pulmonary tuberculosis
JPH0251405B2 (en)
SU1139436A1 (en) Method of treatment of recurring herpes
SU787028A1 (en) Method of treating iron deficiency anemia of children
RU2031655C1 (en) Remedy for treatment of tonsillitis
SU1553129A1 (en) Method of treating algomenorrhea
RU95102611A (en) Method of treatment of pulmonary tuberculosis
RU95104501A (en) Antilymphoglob
SU1034741A1 (en) Tuberculosis treatment method
RU2071342C1 (en) Method of treatment of cirrhotic form of lung tuberculosis
Silver et al. Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission